Gilvetmab is the first and only immune checkpoint inhibitor developed for the treatment of mast cell tumors (MCTs) and melanomas in dogs.
LEARN MOREFor the prevention of early mortality in day-old chickens associated with Escherichia coli, Salmonella typhimurium, and Pseudomonas aeruginosa
LEARN MOREFor the vaccination of healthy pregnant swine to provide passive immunity against rotaviral diarrhea, colibacillosis and enterotoxemia due to…
LEARN MORETriple-action, once-a-day treatment for 7 days for even the most stubborn cases associated with susceptible strains of yeast and bacteria in canines.
LEARN MORE